DURHAM, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) a leading global contract research organization ("CRO"), today announced it has completed the divestiture of assets relating to its Enabling Services segment, namely its Endpoint Clinical ("Endpoint") and Fortrea Patient Access ("FPA") businesses, to Arsenal Capital Partners ("Arsenal"), a leading private equity firm specializing in building market-leading, technology-rich healthcare and industrial growth companies. Endpoint and FPA prov ...

Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea. DURHAM, N.C., June 0 ...

DURHAM, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 am ET. The live webcast will be available to investors and other interested parties by accessing the Fortrea Investor Relations website. A webcast replay will be available after ...

利用真实世界数据、患者见解和系统化的流程，设计、实施和衡量临床试验中多样性行动计划的作用北卡罗来纳州，达勒姆, June 01, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) （以下简称“公司”）, 一家全球领先的合同研究组织 (CRO) ，今天宣布推出全面的综合解决方案，以改善临床试验参与者的多样性和入选 (D&I)。Fortrea 的 D&I 解决方案旨在增加患者参与临床试验的机会，并满足美国食品药品监督管理局 (FDA) 在《食品和药品综合改革法案》下提出的要求，增加临床试验中代表性不足群体参与。 Fortrea 的综合流程整合了多元化行动计划和执行的五个组成部分： 真实世界证据顾问研究相关的真实世界数据集，为多样性计划提供信息。法规、开发和临床运营专家设计多样性行动计划，与患者群体确认并与监管方谈判。运营团队访问多个数据平台、Fortrea 的现场咨询委员会和技术驱动解决方案，将多样性行动计划作为 Fortrea 临床试验执行的一个必要组成部分来实施。通过 Fortrea 独家的多样性和入选研究洞察板，实现监测和报告，提供可操作数据和可视化工具，以进行 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 001-41704 FORTREA HOLDINGS INC. (Exact name of registrant as specified in its charter) INDEX | Delaware | 92-2796441 | | --- | -- ...

DURHAM, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced the appointment of Machelle Sanders to the Company's Board of Directors. Ms. Sanders has served as North Carolina's Secretary of Commerce since February 2021 and brings strong domain expertise from more than 30 years of operational and quality assurance roles in pharmaceutical and biotechnology companies. "Machelle's impressive background in life sci ...

Fortrea Holdings Inc. (NASDAQ:FTRE) Q1 2024 Earnings Conference Call May 13, 2024 8:00 AM ET David Windley - Jefferies Elizabeth Anderson - Evercore Patrick Donnelly - Citi Eric Coldwell - Baird Max Smock - William Blair Michael Ryskin - Bank of America Rishi Parekh - JP Morgan At this time, all participants are in a listen-only mode. After the speakersÂ' presentation, there will be a question and answer session. To ask a question during the session, you will need to press star-one-one on your telephone, yo ...

Q1 2024 Earnings Presentation Learn more at fortrea.com. ©2024 Fortrea Inc. All rights reserved. Fortrea Q1'2024 Earnings presentation 05.13.2024 FORWARD-LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES In light of these risks, uncertainties and assumptions, the forward-looking statements contained in this presentation might not prove to be accurate and you should not place undue reliance upon them. All forwardlooking statements attributable to us or persons acting on our behalf are expressly qualified in t ...

Exhibit 99.1 Fortrea Reports First Quarter 2024 Results For the three months ended March 31, 2024, from continuing operations: DURHAM, N.C., May 13, 2024— Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the first quarter ended March 31, 2024. "We are making solid progress toward our goal of being the best choice among clinical research organizations for customers large and small, creating a positive and distinctive experienc ...

For the three months ended March 31, 2024, from continuing operations: Revenues of $662.1 millionGAAP net loss of $81.6 millionAdjusted EBITDA of $29.5 millionGAAP and adjusted diluted earnings (loss) per share of $(0.91) and $(0.04), respectivelyBook-to-bill ratio of 1.11x, resulting in >1.2x book-to-bill for the trailing nine monthsPlanned divestiture of assets relating to the Endpoint Clinical and Patient Access businesses on track DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the ...